Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022087 · ClinicalTrials.gov registry record · Phase 3
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
A Phase 3 study of Breast Cancer and Osteoporosis, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 439
- Enrollment target
- 20
- Study locations
NCT00022087: Completed Phase 3 study of Breast Cancer and Osteoporosis, sponsored by Alliance for Clinical Trials in Oncology.
NCT00022087 is a Phase 3 study of Breast Cancer and Osteoporosis that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 439 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022087, a Phase 3 study of Breast Cancer and Osteoporosis, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 439 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
Conditions Studied
Interventions
- DRUG zoledronic acid
- DIETARY_SUPPLEMENT cholecalciferol
- DIETARY_SUPPLEMENT calcium salts
Study Locations (20)
Florida
- Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital - Fort Lauderdale
- Memorial Cancer Institute at Memorial Regional Hospital - Hollywood
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center - Jupiter
- CCOP - Mount Sinai Medical Center - Miami Beach
- Cancer Research Network, Incorporated - Plantation
- Cleveland Clinic Florida - Weston - Weston
California
- Arroyo Grande Community Hospital - Arroyo Grande
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- El Camino Hospital - Mountain View
- Naval Medical Center - San Diego - San Diego
- Veterans Affairs Medical Center - San Diego - San Diego
Delaware
- Kent General Hospital at Bayhealth Medical Center - Dover
- Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
- St. Francis Hospital - Wilmington
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
- Washington Cancer Institute at Washington Hospital Center - Washington D.C.
- Sibley Memorial Hospital - Washington D.C.
Illinois
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2001-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
What the finished NCT00022087 record still lists
NCT00022087 is an interventional study that assigns participants to a tested intervention. The registered 439 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which zoledronic acid is the first listed.
NCT00022087 names 20 study sites across 5 states, led by Florida, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT00022087 about?
NCT00022087 is a clinical study titled "Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer". RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus ...
What is the current status of trial NCT00022087?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2001-12. Estimated completion is 2009-02.
What conditions does trial NCT00022087 study?
This clinical trial studies the following conditions: Breast Cancer, Osteoporosis.
What interventions are being tested in trial NCT00022087?
The interventions under investigation include: zoledronic acid (DRUG), cholecalciferol (DIETARY_SUPPLEMENT), calcium salts (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00022087?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022087 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00022087's enrollment target sits among peer trials
439 219th of 1224 higher than 1,006 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05421663 · 439 participants · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia